



DUPLICATE

Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01620K		APPLICATION NO.: 10/654,163		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Timothy J. Guzl et al.				
				FILING DATE: 09/03/2003		GROUP:		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
	AK							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
4	AL	DE 102 23 917 A1	12/11/2003	Germany				
	AM	EP 1 199 306 A1	04/24/2002	Europe				
	AN	EP 0 714 898 A1	06/05/1996	Europe				
1	AO	WO 02/50079 A1	06/27/2002	WIPO				
	AP	WP 03/091256 A1	11/06/2003	WIPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
2	AQ	Adrian M. Senderowicz et al., "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators", <i>J. Natl. Cancer Inst.</i> , 92(5):376-387 (March 1, 2000).						
4	AR	Teruki Honma et al., "Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design", <i>J. Med. Chem.</i> , 44: 4615-4627 (2001).						
	AS	Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62).						
	AT							
	AU							
	AV							
EXAMINER <i>Don McKe</i>				DATE CONSIDERED <i>6/15/04</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Sheet 1 of 1

FORM PTO-100 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.: OC01620K	APPLICATION NO.: 10/654,163
	APPLICANT: Timothy J. Guzik et al.	
	FILING DATE: 09/03/2003	GROUP: 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
✓	AA	US 5,571,813	11/05/1996	Rühter et al.			
	AB	US 5,602,136	02/11/1997	Rühter et al.			
	AC	US 5,602,137	02/11/1997	Rühter et al.			
	AD	US 5,688,949	11/18/1997	Inoue et al.			
	AE	US 5,707,997	01/13/1998	Shoji et al.			
	AF	US 5,919,815	07/06/1999	Bradley et al.			
	AG	US 6,040,321	03/21/2000	Kim et al.			
	AH	US 6,191,131	02/20/2001	He et al.			
	AI	US 6,262,096	07/17/2001	Kim et al.			
	AJ	US 6,413,974	07/02/2002	Dumont et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
✓	AK	EP 0 628 559	04/03/2002	Europe			
	AL	EP 1 334 973	08/13/2003	Europe			
	AM	WO 02/40485	05/23/2002	PCT			
	AN	WO 02/50079	06/27/2002	PCT			
	AO	WO 95/35298	12/28/1995	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AP	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-786.
	AQ	Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>Journal of Medical Chemistry</i> , Page EST:22.3, A-W.
	AR	Metthey et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects", <i>J. Med. Chem.</i> (2003), 46(2): 222-236.
	AS	Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5- α]pyrimidines", <i>J. Med. Chem.</i> (1977), 20(2): 296-299.
	AT	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.
	AU	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243:527-536.
	AV	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.
	AW	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- α]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.
	AX	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- α]pyrimidines.", <i>Chem. Pharm. Bull.</i> (1962), 10: 620-626.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.